Home / Stock ratings / Financial Stocks / CME
Stock rating · Security & Commodity Brokers, Dealers, Exchanges & Services
CME Group Inc. (CME) Stock Rating & Analysis
As of October 6, 2026, MELANY rates CME Group Inc. 58 out of 100 (Hold). Its highest factor score is catalyst setup at 100, and its lowest is valuation at 23.
MELANY ratingRated 2026-10-06CME · composite score
About CME Group Inc.
CME Group, based in Chicago, operates exchanges where investors, suppliers, and businesses trade futures and derivatives tied to interest rates, equity indexes, foreign currencies, energy, metals, and commodities. The Chicago Mercantile Exchange was founded in 1898 and completed its IPO in 2002, after which CME Group merged with rival CBOT Holdings in 2007 and acquired Nymex Holdings in 2008 and NEX in 2018.
Rating as of 2026-10-06 · this is a dated snapshot; the live rating is in the app (Pro, free for 30 days). The price above updates in real time.
Why CME scores 58/100
CME's 8 factor scores run from 23 to 100, and 4 of them sit above its composite of 58. Here is how CME breaks down.
Whether the price looks cheap or expensive against earnings, growth, and peers.
Margins, returns on capital, and balance-sheet strength.
- Gross margin 100%
Direction and relative strength of the recent share-price trend.
History of beating or missing estimates, and where estimates are heading.
- Earnings in 15 days (strong beat history)
What Wall Street price targets and revisions are signalling.
Near-term events that could move the stock.
- Earnings in 15 days
Upside weighed against volatility and drawdown risk.
How the current rate and market regime suits this kind of company.
How CME compares
As of October 7, 2026, CME Group Inc. ranks 21st of 21 in Financial Stocks, where the average score is 66.
Key risks for CME
- No specific company-level red flags detected, monitor macro regime changes
Sector and theme context
CME Group Inc. sits in the Financials / rate cycle theme, which MELANY currently rates 11/100 for strength. Theme strength feeds CME's momentum and catalyst factors above.
Tracking CME
CME Group Inc. rates Hold right now, so MELANY is not flagging a fresh entry. Add CME to a watchlist in the app to follow its rating; an alert the moment it changes is part of Pro, free for 30 days.
How MELANY rates CME
MELANY is a rules-based engine that scores every stock from 0 to 100 across eight weighted factors, then re-scores as new price, earnings, and fundamental data arrive. CME Group Inc.'s 58/100 reflects mature factor weighting for its profile.
Ratings are algorithmic and change with the data. They are research and education, not personalized investment advice.
Frequently asked questions about CME
Is CME Group Inc. (CME) a buy?
As of 2026-10-06, MELANY rated CME Group Inc. Hold with a composite score of 58/100. That is a dated snapshot, not the live rating, and it is an algorithmic reading built from eight factors rather than personalized investment advice. Review the factor breakdown above and the disclaimer below before making any decision.
What is CME Group Inc.'s MELANY score?
CME Group Inc. (CME) has a MELANY composite score of 58/100, combining valuation, business quality, price momentum, earnings track record, analyst sentiment, catalyst setup, risk-adjusted profile, macro fit.
How is the CME stock rating calculated?
MELANY scores CME from 0 to 100 across eight weighted factors using live market and fundamental data, then refreshes the rating automatically as new data arrives.
Should I buy CME Group Inc. stock?
That decision is yours; Market Eyes Live does not give buy or sell advice. What the data says: MELANY rates CME Group Inc. (CME) Hold with a composite of 58/100 as of 2026-10-06. The factor breakdown above shows what is driving that, which is a better basis for a decision than any one-word verdict.
What is the CME stock price forecast?
MELANY does not publish price targets or forecasts for CME. Predicting a future price is exactly the kind of false precision the confidence framework avoids. Instead it scores today's setup, 58/100 across eight factors for CME Group Inc., and re-scores automatically as new price, earnings, and fundamental data arrive.
Is CME stock overvalued or undervalued?
MELANY's valuation factor currently reads 23/100 for CME Group Inc., where a higher score means the price looks more attractive on that measure. Scores in the 70s and above read as attractively priced, the mid range as roughly fair, and low scores as stretched. The factor breakdown above shows what drives CME's read.
What price should I buy CME at?
MELANY is not flagging a fresh entry for CME at its current Hold rating, so there is no entry zone to publish right now. Add CME to a watchlist in the app to follow it; an alert the moment the rating changes is part of Pro, free for 30 days.
What are the risks of buying CME stock?
The top risks MELANY currently flags for CME Group Inc.: No specific company-level red flags detected, monitor macro regime changes. The rating on this page already weighs these against the bullish factors; see the risk-adjusted profile score in the breakdown above.
Is CME Group Inc. a good long-term investment?
For long-term durability the two factors that matter most are business quality, which MELANY scores 84/100 for CME Group Inc., and earnings track record, at 64/100. The 58/100 composite blends those with six shorter-horizon factors. Durable quality at a fair price is the long-term case to test; this is research, not personalized investment advice.
Will CME stock go up?
Nobody can promise a stock's direction, and Market Eyes Live does not predict prices. The measurable part: MELANY's price momentum factor reads 45/100 for CME right now, and the catalyst setup factor tracks whether near-term events could move it. Both re-score automatically as the data changes.
How current is this CME rating?
The rating on this page is a snapshot of MELANY's read as of 2026-10-06. The price shown updates live, but the score is not recomputed on this page. MELANY re-scores CME continuously as new price, earnings, and fundamental data arrive, and the current rating is in the app (Pro, free for 30 days).
How this rating works
Market Eyes Live
Every rating graded in public, CME included
MELANY scores more than 11,000 U.S. stocks and ETFs, PRISM ranks conviction and APEX writes the plan with one entry zone. Free to start on iOS and the web.